Patents Issued in August 6, 2013
  • Variant activin receptor polypeptides and uses thereof
    Patent number: 8501678
    Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: August 6, 2013
    Assignee: Atara Biotherapeutics, Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou, John Lu
  • Cyclic, cystein-free protein
    Patent number: 8501679
    Abstract: A protein selected from the amino acid sequence of the region valine Val(91) to glycine Gly(121) of the mature human tumor necrosis factor, or a portion thereof, with the proviso that the protein comprises at least the amino acid sequence of the region lysine Lys(98) to glutamic acid Glu(116), with the cysteine Cys(101) being replaced by a glycine and an amide bond being formed between the amino group of the side chain of the lysine Lys(98) and the carboxyl group of the side chain of the glutamic acid Glu(116), which activates epithelial ion channels and improves the lung function and which can be used for the manufacture of medicaments for the treatment of diseases associated with the lung function, such as oedemas.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: August 6, 2013
    Assignee: Apeptico Forschung und Entwicklung GmbH
    Inventors: Bernhard Fischer, Rudolf Lucas
  • Antagonists against interaction of PF4 and RANTES
    Patent number: 8501680
    Abstract: The invention relates to polypeptides of amino acid sequence SEQ ID NO: 1 according to formula (1), the use thereof for producing a medicament, and medicaments for the treatment of diseases related to monocyte recruitment.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: August 6, 2013
    Assignee: RWTH Aachen
    Inventors: Christian Weber, Philipp Von Hundelshausen, Rory Koenen
  • Macrocyclic hepatitis C virus serine protease inhibitors
    Patent number: 8501681
    Abstract: The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: August 6, 2013
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Deqiang Niu, Dong Liu, Joel D. Moore, Guoyou Xu, Ying Sun, Yonghua Gai, Datong Tang, Yat Sun Or, Zhe Wang
  • Difluorinated tripeptides as HCV serine protease inhibitors
    Patent number: 8501682
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 22, 2009
    Date of Patent: August 6, 2013
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Yat Sun Or, Zhe Wang
  • Cycloundecadepsipeptide compounds and use of said compounds as a medicament
    Patent number: 8501683
    Abstract: At least one embodiment of the present invention relates to new cycloundecadepsipeptide compounds and to the use of said compounds as a medicament, in particular as antiviral agents, more particularly for preventing or treating Hepatitis C infections or HCV induced disorders.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: August 6, 2013
    Assignee: Debio Recherche Pharmaceutique S.A.
    Inventors: Roland Wenger, Manfred Mutter, Patrick Garrouste, Robert Lysek, Olivier Turpin, Grégoire Vuagniaux, Valérie Nicolas, Laura Novaroli Zanolari, Rafael Crabbé
  • Peptide toxin formulation
    Patent number: 8501684
    Abstract: Procedures are described which use solvents to increase the topical insecticidal activity of toxic insect peptides. These procedures comprise drying the peptides, if needed, followed by the addition of either: 1) a polar organic solvent, with or without water, to a dried peptide, or 2) the addition of polar aprotic solvent or other adjuvant to the dried peptide, followed by the addition of either: 1) a polar organic solvent, with or without water, (where a polar aprotic solvent is added first) or 2) a polar aprotic solvent or other adjuvant to the peptide polar organic solvent (where the polar organic solvent is added first), to the peptide formulation.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: August 6, 2013
    Assignee: Vestaron Corporation
    Inventors: William Tedford, John McIntyre, Daniel Russell, Peter Carlson
  • Process for preparing peptide products for promoting cholecystokinin secretion and use of the peptide products
    Patent number: 8501685
    Abstract: A process for producing a peptide product having cholecystokinin secretion promoting effect, said process comprising hydrolyzing soybean residues with one or more proteases so that the peptide product having cholecystokinin secretion promoting effect is obtained. Also disclosed is the composition containing the peptide product and the use thereof.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: August 6, 2013
    Assignee: Food Industry Research and Development Institute
    Inventors: Yi-Hong Chen, Yu-Hui Liu, Chu-Chin Chen, Shiao-Cheng Chuang, Hsiang-Ling Lai, Chien-Ti Chang, Ming-Yu Hung, Su-Er Liou, Fu-Ning Chien
  • Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
    Patent number: 8501686
    Abstract: The invention generally relates to the use of leptin in the treatment of a leptin-responsive disease or condition in a non-lipodystrophic subject. More particularly, the invention is directed to the use of leptin in the treatment of a fatty liver disease in a non-lipodystrophic subject with a relative leptin deficiency. The invention includes methods for the treatment of nonalcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), and nonalcoholic fatty liver disease (NAFLD) in a non-lipodystrophic subject. The invention includes the treatment of conditions ranging from ectopic lipid accumulation (steatosis) to cirrhosis.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: August 6, 2013
    Assignee: University of Michigan
    Inventors: Elif A. Oral, Charles F. Burant, Thomas L. Chenevert, Hero K. Hussain, Barbara J. McKenna
  • Receptor(SSTR2)-selective somatostatin antagonists
    Patent number: 8501687
    Abstract: SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4 or SSTR5, their administration avoids potential undesirable side effects. By incorporating radioiodine or the like in these SSTR2-selective SRIF antagonists, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, highly radioactive moieties can be N-terminally coupled, complexed or chelated thereto. Because they block the receptor function, they can be used therapeutically to block certain physiological effects which SSTR2 mediates.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: August 6, 2013
    Inventors: Jean E. F. Rivier, Judit Erchegyi, Jean Claude Reubi, Helmut R. Maecke
  • SCGB3A2 as a growth factor and anti-apoptotic agent
    Patent number: 8501688
    Abstract: The present disclosure is generally related to methods of using the secretory protein SCGB3A2 for promoting lung development and treating lung disease. Some embodiments are, for example, methods for treating and inhibiting the development of neonatal respiratory distress. Other embodiments are methods of promoting lung development in damaged or diseased lungs. Also disclosed are methods for inhibiting lung damage due to anti-cancer agents.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: August 6, 2013
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Shioko Kimura, Reiko Kurotani
  • Growth factor-mimicking peptides and uses thereof
    Patent number: 8501689
    Abstract: The present invention relates to a growth factor-mimicking peptide having an activity of the growth factor, and a composition and a method for improving skin conditions or for treating a wound using the same. The growth factor-mimicking peptides of this invention have identical functions or actions to natural-occurring human growth factor, and much better stability and skin penetration potency than natural-occurring growth factor. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on the treatment, prevention and improvement of diseases or conditions demanding growth factor activities. In addition, excellent activity and stability of the peptides of this invention can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: August 6, 2013
    Assignee: Caragen Co., Ltd.
    Inventors: Yong-Ji Chung, Young Deug Kim, Eun Mi Kim, Jun Young Choi
  • Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
    Patent number: 8501690
    Abstract: Methods for facilitating joint immobilization or fusion using selective estrogen receptor modulator (SERM) such as raloxifene are disclosed. The SERM may be administered systemically or locally. In conjunction with SERM, other therapeutic agents such as calcium, vitamin D, bone morphogenetic protein may be administered simultaneously. The method can similarly be applied to facilitate bone repair, bone healing, and connective tissue healing processes in a patient.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: August 6, 2013
    Inventor: John G. Stark
  • Methods for treatment of headaches by administration of oxytocin
    Patent number: 8501691
    Abstract: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: August 6, 2013
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Trigemina, Inc., HealthPartners Research & Education
    Inventors: David C. Yeomans, Martin S. Angst, William H. Frey, II, Daniel I. Jacobs
  • Compositions and methods for altering cocaine esterase activity
    Patent number: 8501692
    Abstract: The present invention relates to compositions and methods for treating and preventing cocaine addiction. In particular, the present invention provides mutated cocaine esterase proteins for use in treating and preventing cocaine addiction.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: August 6, 2013
    Assignee: The Regents of the University of Michigan
    Inventors: Roger K. Sunahara, John J. G. Tesmer, Diwahar Narasimhan, James H. Woods, Mark R. Nance, Elin Edwald
  • Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
    Patent number: 8501693
    Abstract: The present invention relates to altering the concentration of fibrinogen, specifically, for example, by decreasing fibrinogen concentration. The present invention also relates to methods for improving the cardiovascular risk profile of a subject by decreasing fibrinogen concentration.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: August 6, 2013
    Assignees: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LP
    Inventors: Dennis Kim, Michael Trautmann
  • Method of administering porcine B-domainless fVIII
    Patent number: 8501694
    Abstract: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: August 6, 2013
    Assignees: Emory University, Baxter International Inc., Baxter Healthcare SA
    Inventors: John S. Lollar, Garrett E. Bergman
  • Tissue kallikrein for the treatment of diseases associated with amyloid protein
    Patent number: 8501695
    Abstract: This invention relates to methods of treating Alzheimer's disease or symptoms thereof, and amnesic mild cognitive impairment or symptoms thereof. Methods of the invention include administering a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof. The invention further relates to uses of tissue kallikrein or a variant or active fragment thereof for the digesting or cleaving amyloid and the treatment of conditions benefiting from the digestion or cleavage of amyloid. The invention further relates to pharmaceutical compositions comprising a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof formulated for oral or intranasal administration.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: August 6, 2013
    Assignee: DiaMedica, Inc.
    Inventor: Mark Williams
  • Soluble GP130 muteins with improved binding activity
    Patent number: 8501696
    Abstract: Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr102 Gln113 or Asn114 of the N-terminal Ig-like domain of gp130 is mutated to Tyr102, Phe113 or Leu114, respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: August 6, 2013
    Assignee: Conaris Research Institute AG
    Inventors: Joachim Grötzinger, Jürgen Scheller, Stephanie Tenhumberg, Stefan Rose-John, Georg H. Wätzig
  • Crystal structures of SGLT2 inhibitors and processes for preparing same
    Patent number: 8501698
    Abstract: The present invention relates to physical crystal structures of a compound of the formula I: wherein R1, R2, R2a, R3 and R4 are as defined herein, especially pharmaceutical compositions containing structures of compound I or II, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: August 6, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jack Z. Gougoutas, Hildegard Lobinger, Srividya Ramakrishnan, Prashant P. Deshpande, Jeffrey T. Bien, Chiajen Lai, Chenchi Wang, Peter Riebel, John Anthony Grosso, Alexandra A. Nirschl, Janak Singh, John D. DiMarco
  • Bicyclic nucleosides and nucleotides as therapeutic agents
    Patent number: 8501699
    Abstract: The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: August 6, 2013
    Assignee: Biota Scientific Management Pty Ltd
    Inventors: Paula Francom, Barbara Frey, Silas Bond, Alistair George Draffan, Michael Harding, Richard Hufton, Saba Hangiri, Michael John Lilly, Edward Tyndall, Jianmin Duan, Richard Bethell, George Kukolj
  • Method to enhance delivery of glutathione and ATP levels in cells
    Patent number: 8501700
    Abstract: A therapeutic method is provided comprising treating a mammal subject to hypoxia with an amount of 2(R,S)-D-ribo-(1?,2?,3?,4?-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid (RibCys) or a pharmaceutically acceptable salt thereof effective to both maintain, restore or increase both the ATP levels and the glutathione (GSH) levels in said tissue.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: August 6, 2013
    Assignee: Max International LLC
    Inventor: Herbert T. Nagasawa
  • Use of lipid conjugates in the treatment of disease
    Patent number: 8501701
    Abstract: The invention relates to methods of use for compounds in treating, reducing the incidence, reducing the severity or pathogenesis of an intestinal disease or condition in a subject, including, inter alia, inflammatory bowel disease, Crohn's disease, ulcerative colitis, or a combination thereof.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: August 6, 2013
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Saul Yedgar, Moshe Ligumski, Miron Krimsky
  • Overexpression of Wnt ligands and treatment of lytic bone diseases
    Patent number: 8501702
    Abstract: The present invention is drawn to methods of repairing lytic bone lesions and tumor growth in an individual. In this regard, the present invention discloses use of a Wnt ligand either alone or in combination with anti-Wnt signaling antagonist therapy. The individuals who might benefit from such method may include but are not limited to the ones with multiple myeloma, osteoporosis, post-menopausal osteoporosis, fractures, metastatic breast cancer or metastatic prostate cancer.
    Type: Grant
    Filed: December 4, 2007
    Date of Patent: August 6, 2013
    Assignee: Broad of Trustees of the University of Arkansas
    Inventors: John D. Shaughnessy, Jr., Ya-wei Qiang, Shmuel Yaccoby
  • Chimeric oligomeric compounds for modulation of splicing
    Patent number: 8501703
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of a selected target mRNA. Further provided are uses of the disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Methods of enhancing cellular uptake, modulating tissue distribution and enhancing pharmacological activity of RNase H-independent antisense oligonucleotides are also provided.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: August 6, 2013
    Assignees: Isis Pharmaceuticals, Inc., Sarepta Therapeutics
    Inventors: C. Frank Bennett, Nicholas M. Dean, Ryszard Kole, Casey C. Kopczynski
  • Immunosuppression compound and treatment method
    Patent number: 8501704
    Abstract: Provided are methods and antisense oligonucleotide analogs for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection. The oligonucleotide analogs provided herein comprise a targeting sequence complementary to a preprocessed CTLA-4 mRNA region that spans the splice junction between intron 1 and exon 2 of the preprocessed CTLA-4 mRNA. Also provided are methods of use, in which the oligonucleotides are effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45° C., and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: August 6, 2013
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Dan V. Mourich, Patrick L. Iversen, Dwight D. Weller
  • Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
    Patent number: 8501705
    Abstract: Disclosed are methods for treating an autoimmune and/or complement mediated disease or condition in a subject. The methods include administering to the subject a compound which inhibits the subject's classical complement pathway. The methods include administering to the subject a compound which inhibits the subject's classical complement pathway. Compositions which include inhibitors of C1q, C1r, C1s, C2 or C4 and a pharmaceutically acceptable excipient are also described.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: August 6, 2013
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Premkumar Christadoss, Erdem Tuzun
  • Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
    Patent number: 8501706
    Abstract: Provided herein are duplex oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene without the aid of a transfection reagent(s). The duplex oligonucleotide complexes of the disclosure include a conjugate moiety that facilitates delivery to a cell, tissue or organism.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: August 6, 2013
    Assignee: Dharmacon, Inc.
    Inventors: Christina Yamada, Anastasia Khvorova, Rob Kaiser, Emily Anderson, Devin Leake
  • Adenosine compounds and their use thereof
    Patent number: 8501708
    Abstract: Provided herein are a class of purine nucleoside compounds, particularly substituted adenosine compounds, such as benzyloxy cyclopentyladenosine (BCPA) compounds, as well as methods of using these compounds as selective A1 adenosine receptor agonists, particularly for reducing and/or controlling elevated or abnormally fluctuating intraocular pressure (IOP) in the treatment of glaucoma or ocular hypertension (OHT).
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: August 6, 2013
    Assignee: Inotek Pharmaceuticals Corporation
    Inventor: Prakash Jagtap
  • Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
    Patent number: 8501709
    Abstract: The invention is directed to phosphonate nucleosides comprising a phosphonalkoxy-substituted five-membered, saturated or unsaturated, oxygen-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base, as well as pharmaceutical compositions thereof. These compounds, which can be described by general formula (II), are useful for the treatment of retroviral infection, e.g., HIV (Human Immunodeficiency Virus) infection in a mammal. The invention also features synthetic intermediates for the preparation of phosphonate nucleosides.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: August 6, 2013
    Assignee: K.U.Leuven Research & Development
    Inventors: Piet Herdewijn, Christophe Pannecouque, Tongfei Wu, Erik De Clercq
  • Methods of skin treatment and use of water-soluble ?-(1,3) glucans as active agents for producing therapeutic skin treatment agents
    Patent number: 8501710
    Abstract: A method of treating an ulcer comprising applying to the ulcer a preparation comprising a water-soluble ?-(1,3) glucan with ?-(1,6) linked side-chains, where the side-chains comprise ?-(1,3) linkages or up to four consecutive ?-(1,6) linkages as active ingredients.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: August 6, 2013
    Assignee: Biotec Pharmacon ASA
    Inventors: Rolf Engstad, Rolf Seljelid
  • Acylated 1,6-anhydro decasaccharide and its use as an antithrombotic agent
    Patent number: 8501711
    Abstract: The instant invention relates to the decasaccharide of formula (I), wherein Ac represents an acetyl group: in its acid form or in the form of any one of its pharmaceutically acceptable salts, and to its process of preparation. The oligosaccharide of formula (I) is useful as an antithrombotic agent.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: August 6, 2013
    Assignee: Sanofi
    Inventors: Pierre Mourier, Christian Viskov
  • Boron-containing small molecules as anti-inflammatory agents
    Patent number: 8501712
    Abstract: Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: August 6, 2013
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Stephen J. Baker, Virginia Sanders, Tsutomu Akama, Carolyn Bellinger-Kawahara, Yvonne Freund, Kirk R. Maples, Jacob J. Plattner, Yong-Kang Zhang, Huchen Zhou, Vincent S. Hernandez
  • Drug combinations for the treatment of duchenne muscular dystrophy
    Patent number: 8501713
    Abstract: Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: August 6, 2013
    Assignee: Summit Corporation PLC
    Inventors: Graham Michael Wynne, Stephen Paul Wren, Peter David Johnson, Paul Damien Price, Olivier De Moor, Gary Nugent, Richard Storer, Richard Joseph Pye, Colin Richard Dorgan
  • Inhibitors of viruses
    Patent number: 8501714
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: September 7, 2010
    Date of Patent: August 6, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Aesop Cho, Lee S. Chong, Michael O'Neil Hanrahan Clarke, Edward Doerffler, Choung U. Kim, Qi Liu, William J. Watkins, Jennifer R. Zhang
  • Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
    Patent number: 8501715
    Abstract: Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: August 6, 2013
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Jacob George, Gideon Halperin, Itzhak Mendel, Niva Yacov, Eti Kovalevski-Ishai
  • C7-fluoro substituted tetracycline compounds
    Patent number: 8501716
    Abstract: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: August 6, 2013
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Jingye Zhou, Xiao-Yi Xiao, Louis Plamondon, Diana Katharine Hunt, Roger B. Clark, Robert B. Zahler
  • Methods to treat and/or prevent mucositis
    Patent number: 8501717
    Abstract: The present invention relates to methods useful for treating and/or preventing mucositis using an active vitamin D compound.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: August 6, 2013
    Assignee: Merck, Sharp & Dohme Corp.
    Inventor: Chen Zong
  • Androgen treatment in females
    Patent number: 8501718
    Abstract: The present invention is directed to a method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering dehydroepiandrosterone to the female for at least about one month, and evaluating a second anti-Müllerian hormone level of the female, wherein the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: August 6, 2013
    Assignee: American Infertility of New York
    Inventors: Norbert Gleicher, David H. Barad, Dwyn V. Harben
  • Androgen treatment in females
    Patent number: 8501719
    Abstract: The present invention is directed to a method of using dehydroepiandrosterone (DHEA) to treat a human female with diminished ovarian reserve. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of DHEA per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of DHEA per day to the female for at least four months.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: August 6, 2013
    Assignee: American Infertility of New York
    Inventors: Norbert Gleicher, David H. Barad, Dwyn V. Harben
  • Method for treatment of dysmenorrhea
    Patent number: 8501720
    Abstract: A method of treatment of dysmenorrhea in the context of oral contraception characterized by daily administration of ethinylestradiol and drospirenone in an extended regimen.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: August 6, 2013
    Assignee: Bayer Pharma AG
    Inventors: Renate Heithecker, Bernd Duesterberg
  • Postprandial hyperglycemia-improving agent
    Patent number: 8501721
    Abstract: A postprandial hyperglycemia-improving agent, the agent is highly safe and exhibits excellent effects of inhibiting the postprandial increase of blood glucose. The postprandial hyperglycemia-improving agent comprises a cycloartenol or a derivative thereof as an active ingredient.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: August 6, 2013
    Assignee: Kao Corporation
    Inventors: Daisuke Fukuoka, Kohjiro Hashizume, Akira Shimotoyodome
  • Methods and compositions for treating bacterial infection
    Patent number: 8501722
    Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides compounds as therapeutic agents against bacterial infections.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: August 6, 2013
    Assignee: The Regents of the University of Michigan
    Inventors: David Ginsburg, Hongmin Sun, Scott Larsen, Bryan Yestrepsky
  • Pharmaceutical compositions comprising fesoterodine
    Patent number: 8501723
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: August 6, 2013
    Assignee: UCB Pharma GmbH
    Inventors: Hans-Jürgen Mika, Christoph Arth, Michael Komenda, Fatima Bicane, Kerstin Paulus, Meike Irngartinger, Hans Lindner
  • Purinone compounds as kinase inhibitors
    Patent number: 8501724
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: August 6, 2013
    Assignee: Pharmacyclics, Inc.
    Inventors: Wei Chen, David J. Loury
  • Synergistic combination of flumetsulam or diclosulam with zinc pyrithione
    Patent number: 8501725
    Abstract: A synergistic antimicrobial composition containing flumetsulam or diclosulam; and zinc pyrithione.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: August 6, 2013
    Assignee: Dow Global Technologies LLC
    Inventor: Emerentiana Sianawati
  • Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators
    Patent number: 8501726
    Abstract: The present invention relates to novel azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: August 6, 2013
    Assignee: Allergan, Inc.
    Inventors: Wenkui K. Fang, Liming Wang, Evelyn G. Corpuz, Ken Chow, Wha Bin Im
  • Short acting benzothiazepine calcium channel blockers and uses thereof
    Patent number: 8501727
    Abstract: The present invention relates to short-acting calcium channel blocking compounds and their use to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension in general, hypertension been.) fore, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: August 6, 2013
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Dominik Herbart, Harry J. Leighton
  • Substituted heteroarylamide oxazepinopyrimidone derivatives
    Patent number: 8501728
    Abstract: The disclosure relates to a series pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: Y, Z, R1, R2, R3, R4 and n are as defined in the disclosure. Also disclosed are methods of preparing the compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: August 6, 2013
    Assignees: Sanofi, Mitsubishi Tanabe Pharma Corporation
    Inventors: Aude Fayol, Alistair Lochead, Mourad Saady, Julien Vache, Philippe Yaiche
  • 5-HTreceptor modulators, methods of making, and use thereof
    Patent number: 8501729
    Abstract: Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and irritable bowel syndrome. Methods of making these compounds are also described in the present invention.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: August 6, 2013
    Assignee: Albany Molecular Research, Inc.
    Inventors: David D. Manning, Christopher Lawrence Cioffi